Pyrazinamide, but not pyrazinoic acid, is a competitive inhibitor of NADPH binding to Mycobacterium tuberculosis fatty acid synthase I
- 1 August 2011
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (16) , 4804-4807
Abstract
No abstract availableKeywords
Funding Information
- National Science Foundation (CHE0957544)
This publication has 26 references indexed in Scilit:
- The Antituberculosis Drug Pyrazinamide Affects the Course of Cutaneous Leishmaniasis In Vivo and Increases Activation of Macrophages and Dendritic CellsAntimicrobial Agents and Chemotherapy, 2009
- Enhancement of the antituberculosis activity of weak acids by inhibitors of energy metabolism but not by anaerobiosis suggests that weak acids act differently from the front-line tuberculosis drug pyrazinamideJournal of Medical Microbiology, 2008
- Inhibition Kinetics and Emodin Cocrystal Structure of a Type II Polyketide Ketoreductase,Biochemistry, 2008
- Inhibition of Isolated Mycobacterium tuberculosis Fatty Acid Synthase I by Pyrazinamide AnalogsAntimicrobial Agents and Chemotherapy, 2007
- Pyrazinoic Acid and Its n -Propyl Ester Inhibit Fatty Acid Synthase Type I in Replicating Tubercle BacilliAntimicrobial Agents and Chemotherapy, 2007
- Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitroJournal of Antimicrobial Chemotherapy, 2006
- Architecture of a Fungal Fatty Acid Synthase at 5 Å ResolutionScience, 2006
- Architecture of Mammalian Fatty Acid Synthase at 4.5 Å ResolutionScience, 2006
- NMR-Based Screening with Competition Water−Ligand Observed via Gradient Spectroscopy Experiments: Detection of High-Affinity LigandsJournal of Medicinal Chemistry, 2002
- Effects of Pyrazinamide on Fatty Acid Synthesis by Whole Mycobacterial Cells and Purified Fatty Acid Synthase IJournal of Bacteriology, 2002